Toll Free: 1-888-928-9744

Atopic Dermatitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 375 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atopic Dermatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H2 2016', provides an overview of the Atopic Dermatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 11 Introduction 12 Global Markets Direct Report Coverage 12 Atopic Dermatitis Overview 13 Therapeutics Development 14 Pipeline Products for Atopic Dermatitis - Overview 14 Pipeline Products for Atopic Dermatitis - Comparative Analysis 15 Atopic Dermatitis - Therapeutics under Development by Companies 16 Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 22 Atopic Dermatitis - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Atopic Dermatitis - Products under Development by Companies 27 Atopic Dermatitis - Products under Investigation by Universities/Institutes 35 Atopic Dermatitis - Companies Involved in Therapeutics Development 36 AbbVie Inc 36 Accolade Pharmaceuticals, LLC 37 AlbireoPharma 38 Almirall, S.A. 39 Amgen Inc. 40 Amorepacific Corporation 41 Anacor Pharmaceuticals, Inc. 42 AnaMar AB 43 AnaptysBio, Inc. 44 AnGes MG, Inc. 45 arGEN-X BV 46 Avexxin AS 47 Blueberry Therapeutics Ltd 48 Brickell Biotech, Inc. 49 Celgene Corporation 50 Cell Medica Limited 51 Cellceutix Corporation 52 ChemoCentryx, Inc. 53 ChironWells GmbH 54 Chugai Pharmaceutical Co., Ltd. 55 Creabilis SA 56 Curapel Limited 57 Dermala Inc 58 Dr. August Wolff GmbH & Co. KG Arzneimittle 59 Eli Lilly and Company 60 F. Hoffmann-La Roche Ltd. 61 Foamix Pharmaceuticals Ltd. 62 Fountain Biopharma Inc. 63 Galapagos NV 64 GlaxoSmithKline Plc 65 Glenmark Pharmaceuticals Ltd. 66 Grupo Ferrer Internacional, S.A. 67 Han Wha Pharma Co., Ltd. 68 HanAll Biopharma Co., Ltd. 69 Heptares Therapeutics Limited 70 Herantis Pharma Plc 71 iCo Therapeutics Inc. 72 Immune Pharmaceuticals Inc. 73 Inflamalps SA 74 Japan Tobacco Inc. 75 Johnson & Johnson 76 Kang Stem Biotech Co., Ltd. 77 KPI Therapeutics, Inc. 78 LegoChem Biosciences, Inc 79 LEO Pharma A/S 80 Madam Therapeutics B.V. 81 MedImmune, LLC 82 NeoPharm Co., Ltd. 83 Nippon Shinyaku Co., Ltd. 84 Novan, Inc. 85 Novartis AG 86 Orbis Biosciences Inc 87 Otsuka Holdings Co., Ltd. 88 Oxagen Limited 89 Pfizer Inc. 90 Pharis Biotec GmbH 91 Pharmedartis GmbH 92 Provectus Biopharmaceuticals, Inc. 93 PuriCore Plc 94 Quorum Innovations LLC 95 Regeneron Pharmaceuticals Inc 96 Signum Dermalogix, Inc 97 Spherium Biomed S.L. 98 sterna biologicals Gmbh & Co KG 99 Sucampo Pharmaceuticals, Inc. 100 Sun Pharma Advanced Research Company Ltd. 101 SWITCH Biotech LLC 102 Takeda Pharmaceutical Company Limited 103 Thesan Pharmaceuticals, Inc. 104 Tioga Pharmaceuticals, Inc. 105 Torrent Pharmaceuticals Limited 106 Valeant Pharmaceuticals International, Inc. 107 Vicore Pharma AB 108 Vitae Pharmaceuticals, Inc. 109 VivaCell Biotechnology Espana S.L. 110 Xencor, Inc. 111 Ziarco Pharma Ltd 112 Atopic Dermatitis - Therapeutics Assessment 113 Assessment by Monotherapy Products 113 Assessment by Target 114 Assessment by Mechanism of Action 119 Assessment by Route of Administration 124 Assessment by Molecule Type 126 Drug Profiles 128 A-3914 - Drug Profile 128 A-5425 - Drug Profile 129 AKP-11 - Drug Profile 130 Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 132 ALX-101 - Drug Profile 133 AM-1030 - Drug Profile 134 AMG-0101 - Drug Profile 135 Anatabine - Drug Profile 137 ANB-020 - Drug Profile 140 apremilast - Drug Profile 142 Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 153 ARGX-112 - Drug Profile 154 ARN-077 - Drug Profile 155 asimadoline - Drug Profile 156 AVX-001 - Drug Profile 158 B-244 - Drug Profile 159 baricitinib - Drug Profile 160 BB-2702 - Drug Profile 167 BBI-2000 - Drug Profile 168 BBI-5000 - Drug Profile 169 bertilimumab - Drug Profile 170 betamethasone valerate - Drug Profile 174 Biologic for Atopic Dermatitis and Eczema - Drug Profile 175 brilacidin tetrahydrochloride - Drug Profile 176 BTX-1204 - Drug Profile 185 C-21 - Drug Profile 186 CBP-174 - Drug Profile 188 CBP-201 - Drug Profile 189 CCX-6239 - Drug Profile 190 CDE-001 - Drug Profile 191 Cis-Urocanic Acid - Drug Profile 192 cobamamide - Drug Profile 195 crisaborole - Drug Profile 196 CT-101 - Drug Profile 201 CT-103 - Drug Profile 202 CT-327 - Drug Profile 203 CT-340 - Drug Profile 206 cyclosporine - Drug Profile 207 dalazatide - Drug Profile 208 DMT-210 - Drug Profile 213 Drug for Atopic Dermatitis - Drug Profile 214 dupilumab - Drug Profile 215 FB-825 - Drug Profile 221 fevipiprant - Drug Profile 222 FIB-116 - Drug Profile 224 Furestem-AD - Drug Profile 225 GBR-830 - Drug Profile 226 GLPG-2534 - Drug Profile 227 GSK-3772847A - Drug Profile 228 Histimex - Drug Profile 229 HS-378 - Drug Profile 230 IDP-124 - Drug Profile 231 JTE-052 - Drug Profile 232 KPI-150 - Drug Profile 233 LCB-030110 - Drug Profile 234 lebrikizumab - Drug Profile 235 LEKTI-6 - Drug Profile 238 LEO-32731 - Drug Profile 239 LEO-39652 - Drug Profile 240 MEDI-9314 - Drug Profile 241 mepolizumab - Drug Profile 242 MLR-1130 - Drug Profile 247 mometasone furoate - Drug Profile 248 Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 249 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 250 Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile 251 N-oleoylethanolamine - Drug Profile 252 nemolizumab - Drug Profile 253 NPH-12 - Drug Profile 254 NS-141 - Drug Profile 255 OC-000459 - Drug Profile 256 OC-2417 - Drug Profile 258 octenidine hydrochloride - Drug Profile 259 OLX-103 - Drug Profile 260 omiganan pentahydrochloride - Drug Profile 261 OPA-15406 - Drug Profile 263 P-10 - Drug Profile 265 P-148 - Drug Profile 266 PAC-14028 - Drug Profile 267 Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 269 Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 270 PF-04965842 - Drug Profile 271 PH-10 - Drug Profile 272 PL-601 - Drug Profile 275 PMA-101R - Drug Profile 276 PMA-201 - Drug Profile 277 PMA-411R - Drug Profile 278 PR-022 - Drug Profile 279 prednisone - Drug Profile 280 PZ-235 - Drug Profile 281 Q-301 - Drug Profile 282 Qi-507 - Drug Profile 283 roflumilast - Drug Profile 284 RTU-1096 - Drug Profile 289 RVT-501 - Drug Profile 291 SB-011 - Drug Profile 292 SB-414 - Drug Profile 293 secukinumab - Drug Profile 294 SIG-1311 - Drug Profile 307 SIG-1322 - Drug Profile 308 Small Molecule for Atopic Dermatitis - Drug Profile 309 Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 310 Small Molecules for Atopic Dermatitis - Drug Profile 311 Small Molecules for Atopic Dermatitis - Drug Profile 312 Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 313 SP-14019 - Drug Profile 314 SUN-0597 - Drug Profile 315 SWT-01113 - Drug Profile 317 SWT-05141 - Drug Profile 318 Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 319 tacrolimus - Drug Profile 320 tezepelumab - Drug Profile 321 tralokinumab - Drug Profile 323 upadacitinib tartrate - Drug Profile 325 ustekinumab - Drug Profile 327 VTP-38543 - Drug Profile 333 WBI-1001 - Drug Profile 334 WOL-071007 - Drug Profile 336 XmAb-7195 - Drug Profile 337 YJC-10592 - Drug Profile 338 Zafi-1 - Drug Profile 339 ZPL-389 - Drug Profile 340 ZPL-521 - Drug Profile 342 Atopic Dermatitis - Dormant Projects 343 Atopic Dermatitis - Discontinued Products 353 Atopic Dermatitis - Product Development Milestones 355 Featured News & Press Releases 355 Appendix 365 Methodology 365 Coverage 365 Secondary Research 365 Primary Research 365 Expert Panel Validation 365 Contact Us 365 Disclaimer 366
List of Tables
Number of Products under Development for Atopic Dermatitis, H2 2016 23 Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016 24 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Development by Companies, H2 2016 (Contd..4) 29 Number of Products under Development by Companies, H2 2016 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Development, H2 2016 34 Comparative Analysis by Unknown Stage Development, H2 2016 35 Products under Development by Companies, H2 2016 36 Products under Development by Companies, H2 2016 (Contd..1) 37 Products under Development by Companies, H2 2016 (Contd..2) 38 Products under Development by Companies, H2 2016 (Contd..3) 39 Products under Development by Companies, H2 2016 (Contd..4) 40 Products under Development by Companies, H2 2016 (Contd..5) 41 Products under Development by Companies, H2 2016 (Contd..6) 42 Products under Development by Companies, H2 2016 (Contd..7) 43 Products under Investigation by Universities/Institutes, H2 2016 44 Atopic Dermatitis - Pipeline by AbbVie Inc, H2 2016 45 Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 46 Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2016 47 Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2016 48 Atopic Dermatitis - Pipeline by Amgen Inc., H2 2016 49 Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2016 50 Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 51 Atopic Dermatitis - Pipeline by AnaMar AB, H2 2016 52 Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2016 53 Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2016 54 Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2016 55 Atopic Dermatitis - Pipeline by Avexxin AS, H2 2016 56 Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2016 57 Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016 58 Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2016 59 Atopic Dermatitis - Pipeline by Cell Medica Limited, H2 2016 60 Atopic Dermatitis - Pipeline by Cellceutix Corporation, H2 2016 61 Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2016 62 Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2016 63 Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 64 Atopic Dermatitis - Pipeline by Creabilis SA, H2 2016 65 Atopic Dermatitis - Pipeline by Curapel Limited, H2 2016 66 Atopic Dermatitis - Pipeline by Dermala Inc, H2 2016 67 Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016 68 Atopic Dermatitis - Pipeline by Eli Lilly and Company, H2 2016 69 Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 70 Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 71 Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2016 72 Atopic Dermatitis - Pipeline by Galapagos NV, H2 2016 73 Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2016 74 Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 75 Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 76 Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2016 77 Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 78 Atopic Dermatitis - Pipeline by Heptares Therapeutics Limited, H2 2016 79 Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2016 80 Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2016 81 Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2016 82 Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2016 83 Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2016 84 Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2016 85 Atopic Dermatitis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 86 Atopic Dermatitis - Pipeline by KPI Therapeutics, Inc., H2 2016 87 Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016 88 Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2016 89 Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2016 90 Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2016 91 Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2016 92 Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 93 Atopic Dermatitis - Pipeline by Novan, Inc., H2 2016 94 Atopic Dermatitis - Pipeline by Novartis AG, H2 2016 95 Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H2 2016 96 Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 97 Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2016 98 Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2016 99 Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2016 100 Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2016 101 Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 102 Atopic Dermatitis - Pipeline by PuriCore Plc, H2 2016 103 Atopic Dermatitis - Pipeline by Quorum Innovations LLC, H2 2016 104 Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 105 Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016 106 Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2016 107 Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 108 Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 109 Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 110 Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2016 111 Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 112 Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 113 Atopic Dermatitis - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 114 Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 115 Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 116 Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2016 117 Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 118 Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016 119 Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2016 120 Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2016 121 Assessment by Monotherapy Products, H2 2016 122 Number of Products by Stage and Target, H2 2016 124 Number of Products by Stage and Mechanism of Action, H2 2016 129 Number of Products by Stage and Route of Administration, H2 2016 134 Number of Products by Stage and Molecule Type, H2 2016 136 Atopic Dermatitis - Dormant Projects, H2 2016 352 Atopic Dermatitis - Dormant Projects (Contd..1), H2 2016 353 Atopic Dermatitis - Dormant Projects (Contd..2), H2 2016 354 Atopic Dermatitis - Dormant Projects (Contd..3), H2 2016 355 Atopic Dermatitis - Dormant Projects (Contd..4), H2 2016 356 Atopic Dermatitis - Dormant Projects (Contd..5), H2 2016 357 Atopic Dermatitis - Dormant Projects (Contd..6), H2 2016 358 Atopic Dermatitis - Dormant Projects (Contd..7), H2 2016 359 Atopic Dermatitis - Dormant Projects (Contd..8), H2 2016 360 Atopic Dermatitis - Dormant Projects (Contd..9), H2 2016 361 Atopic Dermatitis - Discontinued Products, H2 2016 362 Atopic Dermatitis - Discontinued Products (Contd..1), H2 2016 363



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify